Simulect

In the US, Simulect (basiliximab systemic) is a member of the drug class interleukin inhibitors and is used to treat Organ Transplant, Rejection Prophylaxis.

US matches:

• Simulect

UK matches:

• Simulect 10mg powder and solvent for solution for injection or infusion
• Simulect 20mg powder and solvent for solution for injection or infusion
• Simulect 10mg and 20mg powder and solvent for solution for injection or infusion (SPC)

Ingredient matches for Simulect

Basiliximab

Basiliximab is reported as an ingredient of Simulect in the following countries:

• Argentina


• Australia


• Belgium


• Brazil


• Canada


• Chile


• China


• Colombia


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Ecuador


• Finland


• France


• Germany


• Greece


• Hong Kong


• Hungary


• Iceland


• Ireland


• Israel


• Italy


• Japan


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• New Zealand


• Norway


• Oman


• Peru


• Philippines


• Poland


• Portugal


• Romania


• Russian Federation


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sri Lanka


• Sweden


• Switzerland


• Taiwan


• Thailand


• Tunisia


• Turkey


• United Kingdom


• United States


• Venezuela


• Vietnam

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.